Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084957 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL3694253 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29559656 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29518081 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29997203 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| Hydrochloric Acid SCHEMBL31126002 | 0.99 | CALCRL (0.60) | CALCRLRAMP1 | |
| Water SCHEMBL29518115 | 0.99 | CALCRL (0.60) | CALCRLRAMP1 | |
| SCHEMBL4567288 | 0.90 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL4571727 | 0.87 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL31126005 | 0.87 | CALCRL (0.58) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| EP-4357020-A2 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-4019516-A1 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme Corp. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3680240-A1 | ASYMMETRIC PHASE TRANSFER CATALYSIS | MERCK SHARP & DOHME CORP. (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-2825536-B1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20190275024-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10272077-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9067941-B2 | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150031891-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME CORP. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2825044-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013169574-A2 | ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130267541-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-10-10 | — | — | US | disclosed |
| US-20130267541-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-10-10 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013066360-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267541-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, CNR2 | CALCRL 2/4885RAMP1 72/4885 |
| US-20150031891-A1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | COASY, BCHE, CLK4 | CALCRL 4082/4885RAMP1 4436/4885 |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 67/4885 |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | CALCRL, P2RX3, P2RY1 | CALCRL 1/4885RAMP1 125/4885 |
| US-20190275024-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 63/4885 |
| US-10272077-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB2, CALCR | CALCRL 7/4885RAMP1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.